Trial Profile
Comparison of fesoterodine and mirabegron in the treatment of female overactive baldder patients with urgency incontinence: A randomized, prospective study (Feminine study)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Jan 2017
Price :
$35
*
At a glance
- Drugs Fesoterodine (Primary) ; Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms Feminine
- 21 Jan 2017 Status changed from not yet recruiting to recruiting.
- 04 Nov 2016 New trial record